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We have reacted several derivatives of the anticancer drug cisplatin with N-acetyl-L-
cysteine (N-AcCys) and N-acetyl-L-methionine (N-AcMet), which are two of the 
primary amino acid targets of platinum.  NMR spectroscopy was used to monitor the 
reactions and determine the effect the different ligands would have on the platinum 
reactivity.  Several of the platinum compounds were tested at pH of 4 and 7, and with 
platinum:amino acid ratios of 1:1, 2:1 and 1:2.  Competition reactions between cysteine 
and methionine were done to confirm which would react with the platinum compound 
first. 
[Pt(dien)(NO3)]
+ reacts faster with methionine than with cysteine at both pH 4 and 
7 at a 1:1:1 ratio.  [Pt(N,N,N',N',N"-pentamethyldiethylenetriamine)(NO3)]
+ reacts with 
methionine faster at pH 4 but with cysteine faster at pH 7.  This is most likely due to the 
thiol in the cysteine starting to deprotonate around pH 7.  [Pt(Me4en)(NO3)2] (Me4en = 
N,N,N',N'-tetramethylethylenediamine) forms several products with N-AcCys at both pH 
4 and 7, with the amounts of the products varying depending on the ratio of platinum and 
Cys.  Mass spectrometry indicated one product as {[Pt(Me4en)(H2O)]2(N-AcCys)}
2+, 
with two platinum compounds coordinated to a single cysteine.  Lastly Pt[(en)(NO3)2] 
vii 
when reacting with N-AcCys at a ratio of 1:1 will coordinate with 2 different Cys 




1.1 Brief history of Cisplatin. 
Cisplatin is an anticancer drug that was discovered in the early 1960s used mainly on 
testicular and ovarian cancers.  When added to the anticancer regimen at the time it raised 
the success rates of patients from 14 to 50%.  After some more adjustments to the 
regimen and an increase of the cisplatin dosage the rate increases to 78%.  With modern 
surgery techniques, the rate increases further to ≈95%.  When treating ovarian cancers 
cisplatin has a success rate of 27-29%, when combined with other drugs it increases to 
73%1.  Cisplatin and other platinum complexes like carboplatin and oxaliplatin are useful 
in many types of cancer, such as testicular, ovarian, head and neck, cervical and lung 
cancer.  The use of these drugs can be rather limited due to the body’s natural ability to 
build a resistance to them and due to the somewhat severe side effects.  Potential side 
effects include nephrotoxicity (toxic buildup or damage in the kidneys), emetogenisis 
(vomiting), and neurotixicity (toxic buildup or damage to the neural cells).  The 
nephrotoxicity and emetogenisis can be effectively controlled using hydration, diuretics, 
and serotonin-receptor antagonists.  The neurotoxicity is one of the main reasons that 
cisplatin is dose-limiting, it can cause peripheral neuropathy (weakness or numbness in 
hands and/or feet), tinnitus (a frequent or constant buzzing/ringing in the ear), and the 
loss of the ability to hear high frequencies2. 
 Cisplatin is the first generation of the Platinum (II) class of drugs, but due to its 
side effects the second generation was made, carboplatin and oxaliplatin. These three are 
the only Pt drugs currently used with FDA approval but there are others that are in 
clinical trials.  The later generations were made in an effort to reduce the side effects 
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while keeping a similar effectiveness in killing cancer cells.   On average the later 
generations did indeed reduce the side effects somewhat but also reduced the 
effectiveness against all types of cancer3,4. 
Figure 1.13  The Lewis structures of the 1st and 2nd generation Pt drugs. 
 
1.2 Platinum (II) compound chemistry 
The Platinum (II) compounds are composed of a central Pt atom with 4 ligands.  Those of 
the Cisplatin family have 2 carrier ligands and 2 leaving ligands.  The leaving ligands 
typically would leave the Pt atom very quickly when placed in an aqueous 
environment5,6, though the ligands on Oxaliplatin and Carboplatin tend to stay attached 
until removed by the biological targets. When the ligands leave it creates a positive 
charge on the Pt which allows it to bind to its preferred targets, this usually occurs once 
the Pt compound enters the cell.3,5  The carrier ligands (which are typically some variety 
of nitrate molecule) help the Pt atom to move to the targets, if they are bulky then the 
carrier ligands can also help stop the cell’s DNA Ligase from repairing the damage 
caused by the Pt drug.  Once the Pt compound enter the nucleus, through either active or 
passive transport, its favored target is the N7 positions of 2 Guanine molecules, forming 
either a 1,2 or a 1,3 intrastrand crosslink.  This crosslink will create a “kink” in the DNA 
strand that prevents the cell from repairing or copying the DNA strand, eventually 
leading to apoptosis2,7,8. 
3 
Figure 1.22,3 Graphic of Cisplatin binding to DNA 
 
Cisplatin and most of the related Pt compounds can exist in both the cis- and trans- 
conformations, but only the cis- conformations exhibits the anti-cancer activity.  There 
are other potential targets for the Pt compound to bind to however, including Sulfur 
found in Methionine and Cysteine, Selenium found in Selenomethionine and 
Selenocysteine, or the Nitrogen in Histidine9–15.  These binding tendencies can be 
explained using the Hard/Soft Acid/Base Theory, Pt is acting as a soft acid and is 
attracted to soft bases in the cell, like S and Se, therefor its favored targets would be 
molecules that contain a soft base and is not too allosterically constrained to bind to3,16–20. 
1.3 Previous Research done by the Williams lab. 
There has been previous work done by the Williams research lab pertaining to the 
binding tendencies of Pt compounds.  [Pt(en)NO3]2 with a relatively small diamine ligand 
will react with Met, N-AcMet, 5’-GMP, and Guanosine very well and N-AcHis very 
slowly.  When reacting with Met with excess platinum it binds at the N terminus and 
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forms S,N chelates.  This is similar to what has been seen with oxaliplatin with Met and 
Cys6,21,22.  If coordinated with N-AcMet the product can be displaced by 5’GMP. 
[Pt(en)Cl]Cl interacts with the 5’-GMP phosphate via H+ bonding through the NH2 
groups on the en ligand and the lack of steric hindrance on the en ligand  allows the 
complex to bind unimpeded23,24.  [Pt(Me4en)(NO3)2] is very similar in structure but has 
the added bulk of 4 methyl groups, it reacts in much the same way as the Pt(en)(NO3)2 
but much more slowly.  The rate of reaction with N-AcMet is affected much more than 
with guanosine, indicating that steric hindrance affects the Met ligand more than guanine.  
The only tested target whose binding rate remains unchanged is N-AcHis, implying that 
His targets may be unaffected by the steric hindrance of the carrier ligands.  When 
coordinating with N-AcMet [Pt(Me4en)(NO3)2] will form S,O chelates, specifically with 
the O of the carboxyl group.  The bulk of the carrier ligands only allows binding 
stoichiometry to be 1:1and also prevents coordination of the amide nitrogen atom23,24.  
For [Pt(Et2en)(D2O)2]  the diamine ligand bulk will prevent the coordination of 2 N-
AcMet and prevent the chelation of the amide N of a coordinated N-AcMet. The 
chelation of the O is observed but it occurs slowly.25 Together, these studies indicate that 
steric hindrance on a diamine ligand affects N-AcMet more than it affects 5’-GMP. 
[Pt(dien)NO3]NO3 when reacted with GMP and AcMet, will react with Met faster
14.  
[Pt(Me5dien)NO3]NO3 will coordinate with GMP much faster, it will react with Met only 
very slowly.  If  already coordinated with Met and GMP is added to the solution the GMP 
will displace the Met26.  The preference for 5’-GMP over N-AcMet is so far unique to the 
Me5dien ligand; this was the first example of a platinum compound reacting significantly 
faster with 5’-GMP than with a methionine ligand. 
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  Finally, Pt(dach)(ox) will coordinate with 2 AcMet with little steric hindrance in the 
presence of excess N-AcMet.  Pt(Me2dach)(ox) with the additional bulk of 2 methyl 
groups on the carrier ligands will readily coordinate with one AcMet and will prevent the 
coordination of a second10.  However, the rate of reaction with the first N-AcMet is not 
affected by the presence of one methyl group on each nitrogen atom. 
The binding tendencies of the Pt compounds are affected by several different factors.  
The major factors being pH, the nature of the target site and the size of the carrier ligands 
of the Pt compounds.  The research done by the Williams lab seem to suggest that the 
greatest factor is the size of the carrier ligands.  This project, was focused on trying to see 
if there was a combination of factors that could be used to cause a large carrier ligand Pt 
compound to prefer to bind to the larger AcCys molecule rather than the smaller AcMet.  













II.  Experimental. 
2.1 Purchased Materials 
The following items were purchased from Sigma-Aldrich: Silver Nitrate, Potassium 
Iodide, Acetic Acid, Guanine, L-Histidine, N,N,N’,N’ Tetraethylenetriamine, Dichloro 
(ethylenediamine) platinum (II), cis-Diamminedichloro platinum (II), Sodium Acetate, 
Deuterium Oxide.  N-acetyl-L-Cysteine and Ethylenediamine were purchased from 
Acros.  N-acetyl-L-Methionine was purchased from Fluka. 
2.2 NMR 
A 500 mHz JEOL NMR (Nuclear Magnetic Resonance) was used to characterize the 
results of the reactions.  All samples were dissolved in Deuterium Oxide. The 1H NMR 
spectra were referenced to the residual water signal, adjuster for temperature.  Most of the 
reactions were monitored using several single pulse scans. For several of the reactions a 
kinetics run was used instead.  The kinetics run was set to start a 12 single pulse scans, 
one every hour for 12 hours. 
2.3 LC/MS 
A Varian 500 ion trap mass spectrometer with a Varian 212 HPLC system was used to 
characterize the products of one reaction.  For the experiment 20 µl aliquots of the 
samples were injected with a flow rate of 0.2 ml/min.  Solvent A is 0.1% formic acid in 
water, solvent B is acetonitrile.  At time zero the gradient is 95% A and 5% B, held for 5 
min, pumps were linearly programmed to reach 50% A and 50% B  at 50 min, 10% A 
and 90% B 60 min, 95% A and 5% B 70 min. 
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2.4 Synthesis of [Pt(Me5dien)I]2(Pt2I6) 
.509g K2PtCl4 and .820g KI were mixed in 5 ml Deionized water. The mixture was 
stirred for 30 minutes, after which 250µl Me5dien was added, it was then left to stir 
overnight.  After filtering and leaving the product to air dry 592.4 mg of product was 
collected.  299.2 mg of the product was mixed with 97.4mg of AgNO3 in 20 ml deionized 
water in a 50ml beaker, it covered with aluminum foil and left to stir for 16 hrs.  The 
mixture was then vacuum filtered through celite and the filtrate dried using the roto 
evaporator.  20 ml of diethyl ether was added to the product which stirred for 8 days and 
air dried. 
2.5 Synthesis of Platinum (II) diethylenetriamine [Pt(dien)(NO3)]NO3 
Starting with 1.0024g Potassium Tetrachloroplatinate dissolved in 30 ml of water and 1 
ml diethylenetriamine, adjusted to pH 3.05 with concentrated Hydrochloric acid.  The 
solution is then stirred with a magnetic stir for 7 hours, after stirring for 30 min it was 
thawed to a boil for 6.5 hrs.   The remaining solution was evaporated in a roto evaporator 
until roughly 4 ml and chilled overnight.  It was then evaporated to roughly 3 ml and 
chilled for another night until precipitation had occurred.  Lastly the precipitate was 
vacuum filtered, washed with 2 ml of ethanol, and left to air dry. 
2.6 Synthesis of Platinum (II) N, N, N’, N’ Tetramethylethylenediaminedinitrate, 
Pt(Me4en)(NO3)2 
100.9 mg Pt (Me4en)I2 was dissolved in 110 ml of acetone in a 500 ml round bottom 
flask.  Then 60.3 mg AgNO3 was added, the flask was then sealed with parafilm and 
stirred with a magnetic stir for 5 hours. The solution was gravity filtered twice and the 
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solute was evaporated to dryness using a roto evaporator. This yielded 62.6 mg of Pt 
(Me4en)(NO3)2, confirmed via NMR scan. 
2.7 Previously made compounds 
The following compounds were previously synthesized by other members of the 
Williams lab; [Pt(dien)Cl]Cl, [Pt(dien)(NO3)]NO3, Pt(en)(NO3)2, [Pt(Et4dien)Cl]Cl, 
[Pt(Me5dien)(NO3)](NO3), Pt(Me4en)I2, Me5dien. 
2.8 Preparation of Samples. 
In all 1:1 reactions the reactants were prepared separately in 1 ml of D2O at a 
concentration of 10 mM.  The pH was then adjusted to either pH 4 or 7 as required by the 
experiment.  0.25 ml of each reactant was then mixed together in 0.5 ml of D2O; a 0.7 ml 
aliquot was then put in an NMR tube and scanned accordingly.  In competition reactions, 
the Cysteine and Methionine would be mixed together prior to being mixed with the 
Platinum compound.  In 1:2 reactions the reactants were prepared like the 1:1 method, 
except that instead of double the concentration of the “2” compound we halved the 
concentration of the “1” compound. 
III.  Results 
3.1 [Pt(dien)(NO3)]+ Competition at pH 4 
The sample was prepared as detailed in the methodologies section for competition 
reactions.  This reaction was done to test which amino acid the Pt compound reacts with 








+ Competition at pH 4 at both 19 minutes and 2 days, the “*” 
marks Methionine products and the “ǂ” marks the Cysteine products. 
 
  
The characteristic peaks for Methionine are the peaks closest to 2.0 and 1.9 ppm.  The 
peak for unreacted Cysteine is at 1.95 ppm.  The Methionine product peaks are starting to 
be detected as early as 19 min (marked with the “*”) while the Cysteine product peak has 
yet to form.  After 2 days of reaction time the free Methionine peaks are substantially 











X : parts per Million : 1H
2.5 2.4 2.3 2.2 2.1 2.0 1.92.4 2.0 1.9 
19 min 
* * 



















X : parts per Million : 1H





ppm ppm ppm 
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has started to form around 1.97 ppm (marked with the “‡”) but is approximately one third 
the size of the Methionine product peaks.  This show that under the 1:1:1, pH 4 
conditions Methionine will react faster than Cysteine with [Pt(dien)(NO3)]
+. 
3.2 [Pt(dien)(NO3)]+ Competition at pH 7 
Figure 3.2. [Pt(dien)(NO3)]
+ Competition at pH 7 after a period of 2 days, the “*” marks 






After a period of 2 days (to insure the reaction had reached completion) the characteristic 
peaks for the Methionine products have formed in similar amounts to the pH 4 
experiment.  The Cysteine product peak formed but in only a small amount. This suggests 
that in a competition at pH 7 Methionine will react with [Pt(dien)(NO3)]



















X : parts per Million : 1H
3.5 3.4 3.3 3.2 3.1 3.0 2.9 2.8 2.7 2.6 2.5 2.4 2.3 2.2 2.1 2.0 1.9 1.8 1.7 1.6 1.5 1.4 1.3 1.2 1.1




ppm ppm ppm 
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3.3 Pt(Me5dien)(NO3)]+ with Methionine at pH 4 and pH 7 Comparison   
Figure 3.3.   Pt(Me5dien)(NO3)]
+ with Methionine at pH 4 and pH 7 after a period of 9 
hours, the “*” marks Methionine products. 
 
 
After a period of 9 days, pH 4, and at a 1:1 ratio the Methionine product peaks formed 
well.  At pH 4 Methionine will react readily with Pt(Me5en)(NO3)]
+. However, after 8 
days and at pH 7 very little of the Methionine product peaks have formed.  This suggests 












X : parts per Million : 1H
3.3 3.2 3.1 3.0 2.9 2.8 2.7 2.6 2.5 2.4 2.3 2.2 2.1 2.0 1.9

















X : parts per Million : 1H
3.3 3.2 3.1 3.0 2.9 2.8 2.7 2.6 2.5 2.4 2.3 2.2 2.1 2.0 1.9
3.0 2.5 2.0 
1:1 
* 





3.4 [Pt(Me5dien)(NO3)]+ pH 4 and 7 with Cys Comparison 
Figure 3.4.  [Pt(Me5dien)(NO3)]
+ with Cys at pH 4 and 7 over a period of 2 days, the “ǂ” 
marks the Cysteine products. 
 
 
At pH 4 very little of the expected Cysteine product peaks formed suggesting that very 
little reaction had occurred under these conditions.  At pH 7 the Cysteine product peaks 







3.5 [Pt(Me5dien)(NO3)]+ pH 7 Competition 
Figure 3.5.  [Pt(Me5dien)(NO3)]
+  with Cys and Met at pH 7 after a period of about 2 








When put in competition at pH 7, a strong Cysteine product signal forms but little to no 
Methionine product peaks are seen.  This would suggest that at pH 7 Methionine will 
have little if any reaction with [Pt(Me5en)(NO3)]
+ but Cysteine will react readily. 
3.6 [Pt(Me4en)(NO3)2] pH 4 with Cys 
Figure 3.6. [Pt(Me4en)(NO3)2] with Cys pH 4 after a period of 2 days and at a ratio of 











X : parts per Million : 1H
3.3 3.2 3.1 3.0 2.9 2.8 2.7 2.6 2.5 2.4 2.3 2.2 2.1 2.0 1.9
Y = 12[abn] 
3.0 2.5 2.0 
1:1 
‡ 



























X : parts per Million : 1H
3.3 3.2 3.1 3.0 2.9 2.8 2.7 2.6 2.5 2.4 2.3 2.2 2.1 2.0 1.9
2.5 2.0 
‡ 
ppm ppm ppm 
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Upon completion, the product peaks associated with Cysteine are clearly seen near 1.9 
ppm.  The peaks between 3.0 and 2.5 ppm we did not characterize the product peaks but  
they are likely due to the Me4en ligand and the CH2 of the Cys.   
3.7 [Pt(Me4en)(NO3)2] pH 4 with Cys 2:1 and 1:2 
Figure 3.7.  [Pt(Me4en)(NO3)2] with Cys pH 4 after a period of 2 days and at ratios of 2:1 
and 1:2, “ǂ” marks the Cysteine products.  
 
   
At a ratio of 2:1 Pt:Cys there is a large product peak that are likely associated with 2 Pt 




are smaller and there is a large product peak around 2.8 ppm.  This peak could be due to 
the prevalence of 2 Cys binding to a single Pt as the major product.  
3.8 [Pt(Me4en)(NO3)2] Mass Spectroscopy 
Figure 3.8. Mass spectra and proposed Lewis structure of the 2:1 [Pt(Me4en)(NO3)2] : 
Cys product at pH 4. 
 
The largest peak in the Mass Spectrum is roughly 862 g/ml, which matches the weight of 
the 2 Pt to 1 Cys product. 
3.9 Pt[(en)(NO3)2] at pH 4 with Cysteine in ratios 1:1 and 2:1 


























X : parts per Million : 1H
3.3 3.2 3.1 3.0 2.9 2.8 2.7 2.6 2.5 2.4 2.3 2.2 2.1 2.0 1.9
3.0 2.5 2.0 ppm ppm ppm 





























The signal that appears after 3 days at ≈3.5 (Ϫ) is representative of the ethylene diamine 
ligand being removed from the complex.  This is indicative of both coordination sites 
being occupied by the S of 2 different N-AcCys, which then chelated with the platinum 
atom. 




































X : parts per Million : 1H











X : parts per Million : 1H
3.3 3.2 3.1 3.0 2.9 2.8 2.7 2.6 2.5 2.4 2.3 2.2 2.1 2.0 1.9
3.0 2.5 2.0 ppm ppm ppm 
1:1  3 days 
3.0 2.5 2.0 ppm ppm ppm 


















There is a large unreacted Pt signal present even after 3 days and no signal of displaced 
ethylene diamine ligands.  This implies that with excess Pt the complex preferers to bind 




 The Me5dien ligand has been previously been shown to react faster with Met than 
guanosine. This research shows that at a pH 7, the Me5dien ligand will preferentially bind 
to the S of Cys.  We think there are two reasons for this.  The first is that the steric 
hindrance caused by the ligand will clash with the methyl group on methionine’s S atom 
preventing the Pt from binding while Cys only has a thiol group and therefor has little 
steric hindrance.  The second is that the Pt will react well with Cys at pH 7 due to Cys 
having a pI of 8.1.  At pH 7 some of the Cys molecules are starting to deprotonate the 
thiol groups, creating a charge on the S. Previously it has been shown that Me5dien will 
react faster with 5’-GMP than with methionine, implying that the Pt complex prefers to 
react with DNA over proteins26.  With the added information showing that it will also 



















X : parts per Million : 1H
3.3 3.2 3.1 3.0 2.9 2.8 2.7 2.6 2.5 2.4 2.3 2.2 2.1 2.0 1.9
3.0 2.5 2.0 ppm ppm ppm 
2:1      3 days 
‡ 
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Me5dien will preferentially target cysteine residues.  Potentially changing what proteins it 
will react with and the locations of the binding sites.  Understand how the platinum 
compound ligands affect binding and under what conditions could help in understanding 
where they will preferentially bind to proteins and DNA. 
 The Me4en ligand showed several different products.  At a 1:1 ratio we 
characterized the products using LCMS.  Based on the molecular weight of the major 
product, we believe 2 platinum compounds are bound to the sulfur of the same N-AcCys.  
This shows that the bulk of the Me4en ligand does not cause enough steric hindrance to 
prevent 2 platinum complexes from binding to the same unhindered target site.  This has 
already been seen in published literature with 2 [Pt(dien)]2+ bound to the S of a single 
Glutatione27. 
 The en ligand is small enough that when in a 1:1 ratio the dominant product is 2 
Cys coordinated to the same platinum chelating and removing the en ligands.  This 
implies that there is potential that Pt[(en)(NO3)2] can crosslink when reacting with 
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